Please assess the completion status of the following clinical trial:

Trial Title: Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed Stage IIIB or IV ESCC~* At least experienced one regimens of chemotherapy prior to study~* Histological or cytological evidence of EGFR overexpression or gene copy number increased~* Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)~* Toxicity recovered to NCI CTCAE v.4.03 Grade ≤1 from previous treatments (except alopecia)~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1~* Life expectancy of ≥ 12 weeks~* Adequate organ function~* Subject Consent~* Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to performing this study.~* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.~Exclusion Criteria:~* Prior treatments~* EGFR targeted therapy, or major surgery within 4 weeks prior to study treatment~* Nitrosourea and mitomycin chemotherapy within 6 weeks prior to study treatment~* Had received any investigational agent from other clinical study within 4 weeks prior to study treatment or are currently participating in other clinical trials~* Gastrointestinal diseases that could affect the absorption of Z650, (e.g., serious swallowing obstruction, chronic diarrhea, bowel obstruction);~* Symptomatic, untreated or unstable central nervous system metastases (patient are only permitted if treated, asymptomatic and stable for at least 4 weeks prior to start of study treatment)~* History of interstitial lung disease~* Uncontrolled hypertension that require more than two anti-hypertensive agents to control, or systolic blood pressure (BP) \>140mmHg or diastolic BP \>90 mmHg before the first administration~* Doppler ultrasound evaluation of Left ventricular ejection fraction \< 50%~* Male with QTc interval \> 450 ms or female with QTc interval \> 470 ms~* History of immunodeficiency, or other acquired or congenital immunodeficiency, or history of organ transplantation~* Any disease of the following bellowed within 6 months prior to administration:~Myocardial infarction, or unstable angina, coronary or peripheral artery bypass graft, congestive heart failure, or cerebrovascular events (including transient ischemic attack)~* Active infection of hepatitis B virus (HBV)/hepatitis C virus (HCV), or infection of Human immunodeficiency virus (HIV)~* Other malignancies within 5 years prior to enrollment, with the exception of carcinoma in situ of the cervix, basal or squamous cell skin cancer~* History of serious allergic reactions attributed to excipients of Z650, including mannitol, sodium carboxymethyl starch, aerosol, magnesium stearate and silicified microcrystalline cellulose~* Pregnant women, or patients not agree to use of effective contraceptions during the study or within 6 month after the study~* Any other reason the investigator considers the patient is not suitable to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Z650 , Single-arm (Type: EXPERIMENTAL): Z650 will be administered daily, at dose of 350 mg orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete